当前位置: 首页 > 详情页

Anifrolumab in Systemic Lupus Erythematosus

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Wuhan Childrens Hosp, Wuhan, Peoples R China; [2]Huazhong Univ Sci & Technol, Wuhan, Peoples R China; [3]Wuhan Inst Virol, Wuhan, Peoples R China; [4]Beijing Childrens Hosp, Beijing, Peoples R China; [5]Univ Calif Davis, Davis, CA 95616 USA; [6]Chinese Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China; [7]Inst Maternal & Child Hlth, Wuhan, Peoples R China; [8]Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
出处:
ISSN:

摘要:
To the Editor: Discordant results from the Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP)-1 trial(1) and the TULIP-2 trial (Jan. 16 issue)(2) have stimulated discussion about whether the British Isles Lupus Assessment Group-based Combined Lupus Assessment, the Systemic Lupus Erythematosus Responder Index, or some combination thereof accurately measures response in patients with active systemic lupus erythematosus (SLE).(3,4) Few practicing clinicians could name the components of either assessment, and in my experience, fewer still have ever used them. A simple, clinically meaningful question such as "Do you feel better?" could clarify this debate. Both trials evaluated multiple patient-reported outcome . . .

基金:
语种:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 1 区 医学
小类 | 1 区 医学:内科
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 医学:内科
JCR分区:
出版当年[2018]版:
Q1 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Wuhan Childrens Hosp, Wuhan, Peoples R China;
通讯作者:
通讯机构: [1]Wuhan Childrens Hosp, Wuhan, Peoples R China; [8]Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16461 今日访问量:0 总访问量:871 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院